Journal of cancer research and therapeutics最新文献

{"title":"Mimicry in the abdomen: A rare case of appendiceal carcinoma presenting as appendicitis.","authors":"K S Kanimita, Priyathershini Nagarajan","doi":"10.4103/jcrt.jcrt_771_25","DOIUrl":"10.4103/jcrt.jcrt_771_25","url":null,"abstract":"<p><strong>Abstract: </strong>Apart from usual occurrence of abscess or appendicitis, carcinoma of appendix is quite rare to occur. Yet, here, we describe a reported case of appendiceal adenocarcinoma that clinically presented as appendicitis in a 60-year-old man. The patient presented with pain in right iliac fossa, which was sudden in onset, nonradiating, and progressively increased in severity with complaints of nausea. He had no history of fever, vomiting, cough, or constipation. Computed tomography revealed a well-defined collection with surrounding fat stranding and peritoneal thickening in right iliac fossa measuring 2.6 * 4.2 * 3.5 cm, volume 20 cc. Appendix was retrocecal and thickened with tip leading to the collection. A few prominent mesenteric lymph nodes were seen in right iliac fossa. These features suggested perforated appendix with abscess formation. An open appendicectomy was done under general anesthesia, and the specimen was sent for histopathological analysis. On a surprise note, the microscopic section of the specimen revealed tumor cells with a conventional glandular appearance favoring a diagnosis of moderately differentiated adenocarcinoma, following which an elective right hemicolectomy was advised. Nonspecific symptoms and difficulties in reaching a diagnosis preoperatively may contribute to underreporting of appendiceal carcinomas. Complete surgical excision and/or chemotherapy may be necessary and help in the better prognosis of the patient.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 5","pages":"1079-1081"},"PeriodicalIF":1.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145180685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of submandibular gland involvement in oral carcinoma. A retrospective cohort study.","authors":"Sappidi Sreekanth, Premalatha Shetty, K M Sandeep, Satadru Ray, Sameep Shetty, N Srikant, Nimsi Kola","doi":"10.4103/jcrt.jcrt_789_24","DOIUrl":"10.4103/jcrt.jcrt_789_24","url":null,"abstract":"<p><strong>Background: </strong>Refining the overall survival of oral cancer patients has gained traction in the treatment of oral cancer by offering a good quality of life. Restoring the anatomy and function of the glands in the oral cavity has also been an issue of attention. During every neck dissection, the submandibular gland (SMG) is electively removed as a prophylactic measure. The aim of this study was to evaluate the prevalence of SMG involvement in oral cancer patients and to determine the oncological safety of preserving the SMG during neck dissection in patients with oral cancer.</p><p><strong>Research design and methods: </strong>A total of 215 patients with oral cancer who underwent neck dissection and tumor excision between 2007 and 2018 were included in the study. All data were retrieved from patients treated in a single hospital. Data, including demographics, tumor site, degree of differentiation, involvement of the SMG, Grade of differentiation, and treatment regimens, were collected and evaluated.</p><p><strong>Results: </strong>Oral cancer was predominant in males, with an increased preponderance amongst the age group of 55 to 65 years. The tongue was the predominant tumor subsite. Only 6.5% of all cases involved the submandibular gland, with the majority of cases involved the floor of the mouth as the primary tumor location, followed by Tongue.</p><p><strong>Conclusion: </strong>The present study revealed that SMG involvement occurs mostly when the primary tumor site is in close proximity to the gland, such as the floor of the mouth and tongue. However, metastasis to the SMG from other primary sites is very rare. Hence, the decision regarding the excision of the SMG in oral cancer patients should be made during surgery through meticulous frozen section instead of routine excision of the gland during neck dissection. We recommend preserving the SMG in patients with oral malignancies with no compromise in oncological clearance and remaining cautious while dealing with primary subsites, such as the floor of the mouth and tongue, that are in close vicinity to the submandibular gland.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 5","pages":"1006-1012"},"PeriodicalIF":1.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145180702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current state and future of nonsurgical management of metastatic liver tumors.","authors":"Navesh Sharma, Ashish Nepal, Shreya Sudadi, Rahul Kashyap, Daya Nand Sharma","doi":"10.4103/jcrt.jcrt_192_25","DOIUrl":"10.4103/jcrt.jcrt_192_25","url":null,"abstract":"","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 5","pages":"969-970"},"PeriodicalIF":1.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145180759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neuroendocrine carcinoma of the gall bladder: A clinicopathological report of 56 Cases from a tertiary care cancer center in North India.","authors":"Paramita R Pal, Paramita Paul, Shashikant C U Patne, Zachariah Chowdhury, Ipsita Dhal, Sadaf Haiyat","doi":"10.4103/jcrt.jcrt_1366_24","DOIUrl":"10.4103/jcrt.jcrt_1366_24","url":null,"abstract":"<p><strong>Background: </strong>Gall bladder (GB) is a rare site of neuroendocrine carcinoma (NEC). Gallbladder neuroendocrine carcinoma (GB-NEC) comprises only ~0.2% of all gastrointestinal NECs and 4% of all GB cancers. In the published literature, only a few isolated case reports and rare case series of GB-NEC are available. Worldwide, the largest series of GB-NEC reported is of 19 cases from India. In this study, we present clinicopathological features of 56 cases of GB-NEC diagnosed in a tertiary care cancer hospital of northern part of India.</p><p><strong>Aims: </strong>To study the clinicopathological and immunohistochemical features of GB-NEC from the archives.</p><p><strong>Methods: </strong>Retrospective data of GB-NEC, diagnosed over 53 months were collected from institutional electronic medical records. Hematoxylin and eosin (H and E) stained slides and corresponding immunohistochemistry slides were reviewed and included in the study. Data was compiled and basic statistical analysis was done.</p><p><strong>Results: </strong>GB-NEC constituted 3.19% (n = 56/1752) of all GB carcinomas. Histological types of GB-NEC were: small cell NEC (96.4%, n = 54), large cell NEC (n = 1), and NEC with sarcomatous differentiation (n = 1). The diagnosis was ratified by use of combination of two neuroendocrine markers in varying combination comprising of Synaptophysin, chromogranin and INSMI1. Ki-67 index ranged from 50%-80% in 6 cases and more than 80% in 10 cases where count of mitotic figures was limited by extensive areas of necrosis. Follow-up of 6-8 months was available for 22 patients out of which 21 cases were living with disease. Twenty-two patients were treated with palliative chemotherapy.</p><p><strong>Conclusions: </strong>GB-NEC is a rare and aggressive malignancy with poor prognosis due to advanced clinical stage of presentation and limited availability of treatment options.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 5","pages":"1052-1058"},"PeriodicalIF":1.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145180764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the role of social media and online communities in minimizing the cancer-associated stigma.","authors":"Saurabh RamBihariLal Shrivastava, Prateek Sudhakar Bobhate, Gulshan Ruprao Bandre","doi":"10.4103/jcrt.jcrt_2305_24","DOIUrl":"10.4103/jcrt.jcrt_2305_24","url":null,"abstract":"<p><strong>Abstract: </strong>Cancer has been acknowledged as a global public health concern owing to its universal presence, involvement of different organs, resulting sufferings, impairment in the quality of life, and associated complications, including a fatal outcome. With the rising popularity of social media platforms, there are definite chances that these online forums are the potential drivers and media for spreading stigma. Digital platforms provide a platform for cancer survivors to share their journey and experiences, which contrasts with the traditional stigma resulting from secrecy and isolation in the earlier times. The combination of these merits justifies the need to integrate social media as a part of the comprehensive stigma-reduction initiatives, as they are scalable and cost-effective as well. In conclusion, social media can have both positive and negative consequences on cancer stigma in the community, and remarkably can influence public attitudes and access to cancer care. The need of the hour is to integrate these digital strategies with the traditional approach to create a more knowledgeable and stigma-free environment for people diagnosed with cancer.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 5","pages":"1072-1074"},"PeriodicalIF":1.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145180726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cellular schwannoma of the base of tongue: A case report.","authors":"Mahima Jain, Nikita Gulati, Anshi Jain, Devi Charan Shetty","doi":"10.4103/jcrt.jcrt_726_25","DOIUrl":"10.4103/jcrt.jcrt_726_25","url":null,"abstract":"<p><strong>Abstract: </strong>Schwannomas are solid, well-encapsulated masses that develop eccentrically toward the nerve from that they originate. They typically affect the head and neck and involve Schwann cells surrounding autonomic, peripheral, and cranial nerves. Intraoral schwannoma is most affected by the tongue, with 54% male preponderance. The most common neural tumors in the oral cavity include neurofibroma, schwannoma, and malignant peripheral nerve sheath tumor (MPNST). CD56 is more specific in schwannomas than neurofibromas, with CD56 expressed strongly in 90% of schwannomas and negative in 86% of neurofibromas. Schwannoma has various histological variants, including ancient schwannoma, Cellular schwannoma, epithelioid schwannoma, Microcystic/reticular variant, Neuroblastoma-like variant, and plexiform schwannoma. CD56, when combined with S-100 and calretinin, can help diagnose peripheral nerve sheath tumors like schwannomas and neurofibromas. Surgical excision with nerve preservation is typically curative, but size and location may affect the surgical strategy. Schwannoma management aims to remove the capsule, minimize malignant emergence, and make the prognosis favorable.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 5","pages":"1085-1090"},"PeriodicalIF":1.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145180677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pediatric radiation with daily anesthesia: A critical analysis of risk, complications, and resources.","authors":"Aashita, Abhilash Dagar, Adrija Ghosh, Saurabh Vij, Jitendra K Meena, Shweta Bhopale, Karun Kamboj, Pritee B Chaudhari, Aman Sharma, Akash Kumar, Dayanand Sharma, Supriya Mallick","doi":"10.4103/jcrt.jcrt_2370_24","DOIUrl":"10.4103/jcrt.jcrt_2370_24","url":null,"abstract":"<p><strong>Introduction: </strong>Radiation therapy plays a crucial role in the management of pediatric cancer. With recent advancements in treatment techniques and radiation delivery, stricter immobilization is required. However, achieving this in pediatric patients is challenging and often necessitates daily anesthesia. In this study, we present an audit of pediatric patients who underwent radiation therapy under anesthesia, highlighting associated complications and providing a roadmap for resource allocation.</p><p><strong>Materials and methods: </strong>We collected data on pediatric patients who required radiotherapy under anesthesia, including demographic details, tumor characteristics, anesthesia specifics, observed complications, and any treatment gaps. Descriptive statistics were used to analyze demographic, tumor, and treatment characteristics. Univariate and multivariate analyses were performed to identify correlations with various variables.</p><p><strong>Results: </strong>From January 2021 to December 2023, 67 patients were scheduled for radiotherapy with daily anesthesia. The median age of the patients was 4 years (interquartile range: 2-5 years). Of these, 34 patients required anesthesia for the entire course of treatment, 22 patients needed anesthesia for part of the treatment, and seven patients did not require anesthesia after the simulation. Overall, anesthesia was needed for 59.12% of sessions. Complications occurred in 66 sessions (8.2%) involving 26 patients. Treatment had to be paused in eight cases, with a median delay of 8 days. The treatment compliance rate was 96.9%. An age of <3 years was significantly associated with the need for anesthesia during radiation. The complication rate was notably higher in patients who required anesthesia for the entire course of radiotherapy.</p><p><strong>Conclusion: </strong>While the use of anesthesia ensures proper immobilization during radiation treatment for pediatric patients, it carries the risk of complications. Therefore, it is essential to continuously explore and support efforts to allow patients to undergo radiation without the need for anesthesia.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 5","pages":"1064-1071"},"PeriodicalIF":1.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145180680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of radiation therapy and chemotherapy in locally advanced unresectable nonmetastatic pancreatic cancer patients treated in a tertiary care center.","authors":"Zarmina Alam, Satyajit Pradhan, Abhishek Shinghal, Lincoln Pujari, Akhil Kapoor, Prashanth Giridhar, Ankita Rungta Kapoor, Tanvee, Mayank Tripathi, Ashutosh Mukherji","doi":"10.4103/jcrt.jcrt_1747_24","DOIUrl":"10.4103/jcrt.jcrt_1747_24","url":null,"abstract":"<p><strong>Background: </strong>Locally advanced pancreatic cancer (LAPC) is currently treated with chemotherapy (CT) alone or CT combined with radiation therapy (RT) (CT+RT). There is no robust evidence supporting one over the other. The present study compares the two treatment modalities in terms of their survival outcomes and safety profile.</p><p><strong>Methods: </strong>The retrospective study includes 29 nonmetastatic, unresectable, LAPC patients who were treated with CT+RT (21 patients) or CT alone (8 patients) during November 2019 to September 2023. CT consisted of FOLFIRINOX or Gemcitabine-based regimens. CT+RT patients were treated with conventional (50.4 Gy/28fr) as well as hypofractionated RT dose schedules (39 Gy/13fr, 25 Gy/5fr, and 42 Gy/6fr). The primary endpoint of the study was the median overall survival (OS), and the secondary endpoints were the median progression-free survival (PFS) and acute and late radiation-induced toxicities.</p><p><strong>Results: </strong>At a median follow-up of 24 months, patients of CT+RT group had prolonged survival compared to patients of CT alone group with median OS of 20 months versus 7 months (P = 0.0032) and median PFS of 15 months versus 5 months (P = 0.029). The majority of toxicities in CT+RT group were Grade 1-2 around 79%. However, Grade 3 or more late event was seen only in 1 (5%) patient.</p><p><strong>Conclusion: </strong>Incorporating radiation therapy along with CT should be the standard approach for unresectable LAPC patients improving survival with acceptable toxicities.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 5","pages":"1000-1005"},"PeriodicalIF":1.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145180733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical outcomes with combination of stereotactic body radiation therapy in patients with hepatocellular carcinoma.","authors":"Puja Sahai, Aprajita Mall, Ajit P Solanky, Vaishak Jawahar, Mangu S Bharadwaj, Jasim Jaleel, Deepak Jagya, Guresh Kumar, Saggere M Shasthry, Hanuman P Yadav","doi":"10.4103/jcrt.jcrt_2351_24","DOIUrl":"10.4103/jcrt.jcrt_2351_24","url":null,"abstract":"<p><strong>Purpose: </strong>The purpose of the present study was to evaluate outcomes with a combination of stereotactic body radiation therapy (SBRT) for patients with hepatocellular carcinoma (HCC).</p><p><strong>Materials and methods: </strong>The present retrospective study included 46 patients with 1-3 liver lesions with portal vein tumor thrombosis (PVTT) in 27 treated with definitive, consolidative, or salvage SBRT. The patients had Barcelona Clinic Liver Cancer (BCLC) stage A, B, or C disease (n = 44) with new, residual, progressive, or recurrent lesions with prior liver-directed and/or systemic therapy (n = 37). The median combined maximum diameter of the lesions was 7.48 cm (range, 1.55-16.5 cm). The dose fractionation for SBRT was 24-50 Gy in 5-8 fractions (median = 30 Gy in 6 fractions) with volumetric modulated arc technique on linear accelerator. Systemic treatment with sorafenib, lenvatinib, and/or nivolumab was given in 35 patients. Liver-directed interventional treatment after SBRT was given in 10 patients. Treatment response was evaluated as per mRECIST with or without Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST), and Kaplan-Meier survival analysis was performed.</p><p><strong>Results: </strong>Patient-reported relief in symptoms was observed in 59.4% after SBRT. Of 46, 27 (58.7%) had decreased serum tumor markers with AFP and/or PIVKA-II at 3 months after SBRT with systemic treatment. The median overall survival (OS) was 21.4 months (95% CI: 14.3-28.5 months) after the index cancer diagnosis. The 6-month, 1-year, 2-year, and 3-year OS rates after diagnosis were 84.8%, 60.6%, 44.7%, and 28.2%, respectively. The median OS was 25.3 months versus 10.9 months in patients without versus with PVTT, respectively. Early response at 3-4 months after SBRT with systemic therapy (complete or partial (n = 29) versus stable or progressive (n = 17)) showed an independent association with OS (P ≤ 0.001, hazard ratio (HR) 3.88, 95% CI: 1.94-7.77). The estimated 1-year and 2-year local control rates in all patients were 94.1% and 89.6% after SBRT with systemic therapy. One patient had conversion surgery. Grade 3 hepatic toxicity during SBRT was 10.9%. Liver dysfunction with a Child-Pugh score of 2 or more points within 3 months after SBRT with systemic therapy was noted in 27.3% of patients. Late gastrointestinal toxicity was observed in 1 patient (2.17%).</p><p><strong>Conclusion: </strong>The present study suggested that a combination of radiotherapy with other liver-directed and/or systemic treatments is associated with favorable disease control and prolongation of survival in patients with early to advanced-stage HCC.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 5","pages":"1013-1025"},"PeriodicalIF":1.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145180753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase-II randomized study of carboplatin plus capecitabine versus 3-weekly cisplatin in locally advanced head-and-neck cancer patients undergoing concurrent chemoradiation (CARCAP-HN).","authors":"Srigopal Mohanty, Kallolinee Samal, S G D Gangadaran, Jayaraman Kannan, B Ramkumar, S Saravanan","doi":"10.4103/jcrt.jcrt_2510_24","DOIUrl":"10.4103/jcrt.jcrt_2510_24","url":null,"abstract":"<p><strong>Background: </strong>A substantial proportion of locally advanced head-and-neck squamous cell cancer (LAHNSCC) patients remain ineligible for cisplatin-based chemoradiation due to its frequent toxicities. The study was conducted to compare carboplatin plus capecitabine versus 3-weekly cisplatin in LAHNSCC patients undergoing definitive chemoradiation.</p><p><strong>Materials and methods: </strong>In this phase II randomized trial, stage 3 or 4 laryngeal or pharyngeal cancer patients received radiation dose of 66-70 gray in 33-35 fractions and were randomized (1:1) to weekly carboplatin (AUC 1.5) plus capecitabine 850 mg/m2/day on the radiation days versus 3-weekly cisplatin (50 mg/m2 on day 1 and day 2). The primary endpoints were objective response rate (ORR) and progression-free survival (PFS). Secondary endpoints included grade ≥ 3 treatment toxicities and treatment interruption rate (TIR). The study is registered with CTRI number CTRI/2020/11/029290.</p><p><strong>Results: </strong>A total of 81 patients were studied, 40 in the experimental and 41 in the control arm. At a median follow-up of 12.5 months, the median PFS was 14 months versus 12.5 months (P = 0.715). The ORR was 97.5% versus 94.7%, whereas the complete response rate was 57.5% versus 42.1% in the experimental and control arm, respectively (P = 0.449). Significantly lower grade ≥3 toxicity was observed in the experimental arm, i.e., oral mucositis (P = 0.000), vomiting (P = 0.000), nephropathy (P = 0.014), dyselectrolytemia (P = 0.013), fatigue (P = 0.006), anorexia (P = 0.004). The TIR was significantly lower in the experimental arm (P = 0.000).</p><p><strong>Conclusions: </strong>Carboplatin plus capecitabine-based chemoradiation shows similar efficacy with lesser toxicity compared to 3-weekly cisplatin-based chemoradiation in LAHNSCC.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 5","pages":"1032-1037"},"PeriodicalIF":1.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145180716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}